Skip to content
10-Q

Quarterly Report

Nabriva Therapeutics plc

0001558370-23-010302

← back to feed
Filed
May 22, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Apr 30, 2023 3.2M sh
Shares Diluted Q1 2023 · Mar 31, 2023 3.2M sh
Shares Diluted restated Q1 2023 · Mar 31, 2022 2.35M sh
Capex Q1 2023 · Mar 31, 2023 $3K
Capex Q1 2023 · Mar 31, 2022 $35K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$5.62M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$15.87M
Long Term Debt Q1 2023 · Mar 31, 2023 $345K
Long Term Debt Q1 2023 · Dec 31, 2022 $388K
Short Term Debt Q1 2023 · Mar 31, 2023 $197K
Short Term Debt Q1 2023 · Dec 31, 2022 $4.83M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $1.8M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $12.41M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$4.36M
Stockholders Equity Q1 2023 · Dec 31, 2022 $3.29M
Stockholders Equity Q1 2023 · Mar 31, 2022 $44.63M
Stockholders Equity Q1 2023 · Dec 31, 2021 $53.35M
Current Liabilities Q1 2023 · Mar 31, 2023 $28M
Current Liabilities Q1 2023 · Dec 31, 2022 $27.61M
Total Liabilities Q1 2023 · Mar 31, 2023 $28.7M
Total Liabilities Q1 2023 · Dec 31, 2022 $28.47M
Current Assets Q1 2023 · Mar 31, 2023 $23.69M
Current Assets Q1 2023 · Dec 31, 2022 $31.1M
Total Assets Q1 2023 · Mar 31, 2023 $24.34M
Total Assets Q1 2023 · Dec 31, 2022 $31.77M
Eps Diluted Q1 2023 · Mar 31, 2023 −$2.72
Eps Diluted restated Q1 2023 · Mar 31, 2022 −$5.03
Eps Basic Q1 2023 · Mar 31, 2023 −$2.72
Eps Basic restated Q1 2023 · Mar 31, 2022 −$5.03
Sga Expense Q1 2023 · Mar 31, 2023 $9M
Sga Expense Q1 2023 · Mar 31, 2022 $12.7M
Rd Expense Q1 2023 · Mar 31, 2023 $2.63M
Rd Expense Q1 2023 · Mar 31, 2022 $3.52M
Net Income Q1 2023 · Mar 31, 2023 −$8.7M
Net Income Q1 2023 · Mar 31, 2022 −$11.82M
Operating Income Q1 2023 · Mar 31, 2023 −$8.48M
Operating Income Q1 2023 · Mar 31, 2022 −$11.56M
Cost Of Revenue Q1 2023 · Mar 31, 2023 $4.44M
Cost Of Revenue Q1 2023 · Mar 31, 2022 $3.36M
Revenue Q1 2023 · Mar 31, 2023 $7.59M
Revenue Q1 2023 · Mar 31, 2022 $8.02M